Aging Population And Tech Will Shape Long-Term Medicare Care

Humana's analyst price target has moved from $502 to $513 as analysts point to improving visibility on Medicare Advantage cost trends, margin recovery potential, and a series of higher long term earnings estimates across multiple research firms.

Analyst Commentary

Recent research on Humana shows a cluster of more constructive views, with many bullish analysts pointing to Medicare Advantage cost trends, margin recovery potential, and longer term earnings power as key considerations for valuation.

Across the Street, a number of firms have moved ratings higher or raised price targets into a US$370 to US$513 range. These changes often reference Humana's 2026 outlook, expectations for Stars outcomes, and the earnings contribution of newer Medicare Advantage members.

One group of bullish analysts is leaning on Humana's focus on margins and plan quality. Some see Stars improvement and plan level margin expansion as key inputs into higher 2028 earnings estimates and use those figures to support higher price targets, in some cases above US$470 per share.

Several research notes also emphasize that the company reiterated its 2026 adjusted EPS target of at least US$9.00 and frame that figure as a base case for their models. From there, they layer in potential margin gains from repricing, benefit changes in 2027, and maturing membership, which they argue can support higher long term earnings power.

There is still caution in the mix. At least one firm downgraded Humana to a more neutral stance and highlighted upcoming Star ratings decisions as a binary event with meaningful downside and upside scenarios. That view underlines how much of the current thesis still depends on regulatory and program outcomes that will only become clear closer to 2028.

Other analysts describe the managed care sector as more stable and predictable, which, in their view, allows investors to focus more on company execution, pricing, and cost control. In that context, Humana's emphasis on margin recovery, Stars recapture, and disciplined growth in Medicare Advantage is seen as central to the stock's appeal.

Investors looking at this research mix can see a wide spread in price targets and rating stances. The common threads across the bullish work are attention to earnings visibility through 2026, confidence in margin actions in 2027 and beyond, and the belief that Stars scores and cost trend data will be critical for how Humana is valued over the next few years.

Bullish Takeaways

• Several bullish analysts have upgraded Humana or shifted to more positive ratings while lifting price targets into a US$370 to US$513 range. These moves reflect stronger conviction in earnings potential and margin recovery.
• Research that applies valuation multiples to higher 2028 EPS estimates, in some cases above US$30 per share, presents Humana as having meaningful upside if Stars recapture and margin expansion plans remain on track.
• Multiple firms point to Humana's reiterated 2026 adjusted EPS of at least US$9.00 as a base and see further value if Medicare Advantage margins move closer to 3%, with some estimating several dollars of additional EPS from that shift.
• Bullish analysts highlight a combination of improving cost trend visibility, enterprise wide earnings growth potential, and focused efforts to move members into higher quality plans as key supports for higher long term valuation.

What’s in the News for Humana

• Humana subsidiary Independent Care Health Plan, or iCare, was selected by the Wisconsin Department of Health Services to serve Family Care and Family Care Partnership programs across the greater southeast region, expanding iCare’s presence to all seven counties in the service area and marking a third consecutive Wisconsin geographic win. Source: company announcement via Wisconsin DHS selection.
• Humana plans to exit additional Medicare Advantage plans in 2027, which is expected to affect about 600,000 members, as the company reshapes its Medicare Advantage portfolio and targets a sustainable 3% pre tax margin by 2028 while focusing on higher performing plans. Source: recent press coverage.
• Humana revised its 2026 GAAP EPS guidance to at least US$6.52 from at least US$8.36, providing investors with a refreshed reference point for longer term earnings discussions and analyst models. Source: company guidance update.
• Humana was selected by the Illinois Department of Healthcare and Family Services to serve members statewide in HealthChoice Illinois, the Medicaid managed care program that spans 102 counties, with Humana’s HealthChoice plan slated to go live in January 2027. Source: company client announcement.
• Humana’s CenterWell Pharmacy began full operations at a new US$83 million mail order distribution center in Orlando, Florida, which can process up to 64,000 prescriptions per day and is designed to support prescription delivery for members in Florida and across the southeast United States. Source: company business expansion update.

Valuation Changes for Humana

• Fair Value has risen slightly from $502.00 to $513.00, which is an increase of about 2.2%.
• Discount Rate has risen slightly from 7.13% to 7.32%, implying a modestly higher required return in the updated model.
• Revenue Growth has fallen from 14.85% to 12.56%, indicating a lower assumed dollar revenue growth rate in the new assumptions.
• Profit Margin has risen slightly from 1.91% to 2.02%, pointing to a modestly higher expected level of dollar earnings relative to dollar revenue.
• Future P/E has fallen slightly from 18.51x to 17.94x, which reflects a lower valuation multiple applied to expected earnings.